.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Fuji
Medtronic
Dow
McKinsey
Healthtrust
US Department of Justice
Boehringer Ingelheim
Cerilliant
Julphar

Generated: September 24, 2017

DrugPatentWatch Database Preview

Pharmacia Company Profile

« Back to Dashboard

What is the competitive landscape for PHARMACIA, and when can generic versions of PHARMACIA drugs launch?

PHARMACIA has one hundred and thirty-seven approved drugs.

There are nine US patents protecting PHARMACIA drugs.

There are two hundred and eleven patent family members on PHARMACIA drugs in forty-six countries.

Summary for Applicant: Pharmacia

Patents:9
Tradenames:111
Ingredients:86
NDAs:137
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn
DELTASONE
prednisone
TABLET;ORAL009986-005Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
DOXORUBICIN HYDROCHLORIDE
doxorubicin hydrochloride
INJECTABLE;INJECTION050629-002May 3, 1988APRXYesYes► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
DOXORUBICIN HYDROCHLORIDE
doxorubicin hydrochloride
INJECTABLE;INJECTION050467-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
AZULFIDINE
sulfasalazine
SUSPENSION;ORAL086983-001Approved Prior to Jan 1, 1982RXNoYes► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
MICRONASE
glyburide
TABLET;ORAL017498-002May 1, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
PROTAMINE SULFATE
protamine sulfate
INJECTABLE;INJECTION007413-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
DEPO-TESTOSTERONE
testosterone cypionate
INJECTABLE;INJECTION085635-003Approved Prior to Jan 1, 1982AORXNoYes► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
DELTASONE
prednisone
TABLET;ORAL009986-002Approved Prior to Jan 1, 1982DISCNYesNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
HYLOREL
guanadrel sulfate
TABLET;ORAL018104-002Dec 29, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Pharmacia And Upjohn
CAVERJECT
alprostadil
INJECTABLE;INJECTION020379-001Jul 6, 1995APRXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Pharmacia

Paragraph IV activity for PHARMACIA drugs

Drugname Dosage Strength Tradename Submissiondate
linezolid
Injection2 mg/mL, 100 mL bag
ZYVOX
12/29/2009
linezolid
Injection2 mg/mL, 300 mL bag
ZYVOX
9/1/2009
linezolid
Oral Suspension100 mg/5 mL
ZYVOX
8/3/2009
tolterodine tartrate
Extended-release Capsules2 mg and 4 mg
DETROL LA
7/30/2007
linezolid
Tablets600 mg
ZYVOX
12/21/2005
colestipol hydrochloride
Tablets1 g
COLESTID
8/23/2005

Non-Orange Book Patents for Pharmacia

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,955,346 Variants of human prolactin and human placeatal lactogen► Subscribe
6,143,523 Human growth hormone variants► Subscribe
6,004,931 Method for inhibiting growth hormone action► Subscribe
6,057,292 Method for inhibiting growth hormone action► Subscribe
5,534,617 Human growth hormone variants having greater affinity for human growth hormone receptor at site 1► Subscribe
5,780,279 Method of selection of proteolytic cleavage sites by directed evolution and phagemid display► Subscribe
6,444,813 Linezolid-crystal form II► Subscribe
6,428,954 Method for identifying active domains and amino acid residues in polypeptides and hormone variants► Subscribe
6,780,613 Growth hormone variants► Subscribe
5,750,373 Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Pharmacia Drugs

Country Document Number Estimated Expiration
Hungary0301076► Subscribe
Austria354390► Subscribe
Canada2400118► Subscribe
European Patent Office1568771► Subscribe
Norway20002754► Subscribe
Slovakia12092002► Subscribe
Australia3275501► Subscribe
Slovakia15982002► Subscribe
TaiwanI256310► Subscribe
JapanH04502454► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Pharmacia Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
401Luxembourg► SubscribePRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
/2002Austria► SubscribePRODUCT NAME: LINEZOLID; NAT. REGISTRATION NO/DATE: 1-24227 - 1-24230 20011009; FIRST REGISTRATION: GB PL 00032/0259 - PL 00032/0262 20010105
C/GB01/025United Kingdom► SubscribePRODUCT NAME: LINEZOLID; REGISTERED: UK PL 00032/0259 20010105; UK PL 00032/0260 20010105; UK PL 00032/0261 20010105; UK PL 00032/0262 20010105
C0038France► SubscribePRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
2009Austria► SubscribePRODUCT NAME: KOMBINATION AUS ESTRADIOLVALERAT UND DIENOGEST; NAT. REGISTRATION NO/DATE: 1-28003 20090203; FIRST REGISTRATION: BE BE 327792 20081103
/2004Austria► SubscribePRODUCT NAME: DROSPIRENON IN KOMBINATION MIT ESTRADIOL; NAT. REGISTRATION NO/DATE: 1-25178, 1-25179 20031127; FIRST REGISTRATION: NL RVG 27505 20021211
C/GB96/053United Kingdom► SubscribePRODUCT NAME: DOXORUBICIN SULPHATE; REGISTERED: UK EU/1/96/011/001 19960621; UK EU/1/96/011/002 19960621
60031Netherlands► SubscribePRODUCT NAME: DOXORUBICINESULFAAT VERKREGEN UIT DOXORUBICINEHYDROCHLORIDE EN AMMONIUMSULFAAT; REGISTRATION NO/DATE: EU/1/96/011/001 - EU/1/96/011/002 19960621
C/GB04/032United Kingdom► SubscribePRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Department of Justice
Chubb
Baxter
Mallinckrodt
Dow
Cipla
Farmers Insurance
AstraZeneca
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot